Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hong Jun Yun

Interventional Cardiology Palos Park, IL Medical Doctor

NPI 1396065884 CMS profile 1199882

13011 S 104Th Ave Ste 100, Palos Park, IL 60464

Open in the dashboard

General payments

$88,964

335 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$38,673 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Hong Jun Yun of Palos Park, IL is reported in the CMS Open Payments database as having received $88,964 across 335 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $38,673 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,996 75
2024 General $16,093 50
2023 General $20,128 68
2022 General $30,102 76
2021 General $5,730 24
2020 General $276 6
2019 General $4,638 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hong Jun Yun
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Hong Jun Yun were reported at $11,996. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Hong Jun Yun Interventional Cardiology median Middle half National median
2019 $4,638 $1,097 $329–$3,048 $163
2020 $276 $473 $161–$1,480 $114
2021 $5,730 $677 $233–$1,827 $132
2022 $30,102 $978 $333–$2,724 $149
2023 $20,128 $1,136 $382–$2,986 $160
2024 $16,093 $1,181 $395–$3,326 $164
2025 $11,996 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $72,228 171 payments
  2. Medtronic Vascular, Inc. $4,280 31 payments
  3. Edwards Lifesciences Corporation $3,456 25 payments
  4. CathWorks, Inc. $3,146 4 payments
  5. Boston Scientific Corporation $2,707 17 payments
  6. Abbott Laboratories $1,086 14 payments
  7. W. L. Gore & Associates, Inc. $226 2 payments
  8. Cardiva Medical, Inc. $225 8 payments
  9. Novartis Pharmaceuticals Corporation $178 9 payments
  10. Shockwave Medical, Inc $176 1 payment
  11. Other $1,256 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $53,650 28 payments
  2. Travel and Lodging $19,971 51 payments
  3. Food and Beverage $10,828 251 payments
  4. Consulting Fee $4,500 4 payments
  5. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. COREVALVE EVOLUT R $66,423 135 payments
  2. CoreValve Evolut Transcatheter Valve Systems $5,014 8 payments
  3. FFRangio $3,146 4 payments
  4. Resolute $2,267 17 payments
  5. CoreValve Evolut Transcatheter Valve Systems $1,810 9 payments
  6. AVVIGO Guidance System $1,519 2 payments
  7. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $1,479 9 payments
  8. EVOQUE $1,169 7 payments
  9. TRICLIP $870 9 payments
  10. SAPIEN 3 Ultra RESILIA $416 5 payments
  11. Other $4,480 126 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

4,003

Median for Cardiology: 2,533

Drug cost

$476,893

Median for Cardiology: $485,213

Branded share of claims

20.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 216 $273,436
Entresto Sacubitril/Valsartan Brand 57 $89,554
Xarelto Rivaroxaban Brand 48 $58,735
Brilinta Ticagrelor Brand 13 $10,002
Metoprolol Succinate Generic 564 $9,114
Atorvastatin Calcium Generic 596 $6,787
Clopidogrel Clopidogrel Bisulfate Brand 343 $3,635
Diltiazem 24hr Er (La) Diltiazem Hcl Brand 37 $2,409
Amlodipine Besylate Generic 245 $1,906
Metoprolol Tartrate Generic 288 $1,865

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 86 billing codes

Paid by Medicare

$422,580

Of which drugs: $835

Medicare patients

1,892

Average age 77

Services billed

5,090

932 women, 960 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 65%
Arthritis 54%
Atrial fibrillation 41%
Heart failure 40%
Diabetes 38%
Chronic kidney disease 38%
COPD 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 32 128 $835

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FUROSCIX
  • SCPHARMACEUTICALS INC. $40
$40 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $30
$30 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $16
$16 48 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

335 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record